康龍化成(03759.HK)擬1.2億美元收購境外公司100%股權
格隆匯 3 月 1日丨康龍化成(03759.HK)發佈公吿,董事會會議審議通過《關於收購境外公司100%股權的議案》。公司的核心發展戰略是持續打造並不斷完善深度融合的全流程一體化和國際化的藥物研發服務平台。為此,公司需進一步加強全流程一體化服務平台的建設並繼續加強全球化佈局,本次收購有利於公司更好地整合資源,完善全流程一體化平台建設,符合公司長遠發展規劃及全體股東利益。同意公司以自有資金預計約1.2億美元收購AGN Sundry LLC(以下簡稱“AGN”或“賣方”)所持有的 Allergan Biologics Limited(以下簡稱“ABL ”)的100%股權。
公司將根據本次交易最終交易金額向全資子公司Pharmaron (Hong Kong) International Limited(簡稱“康龍(香港)國際”)增資,通過康龍(香港)國際設立的全資子公司Pharmaron Biologics (UK) Holdings Limited 購買ABL公司100%股權。本次交易完成後,公司將通過全資子公司 Pharmaron Biologics (UK) Holdings Limited持有ABL的100%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.